RTTR - Ritter Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.9798
-0.0202 (-2.02%)
As of 2:23PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.0000
Open1.0000
Bid0.9700 x 1000
Ask0.9895 x 2200
Day's Range0.9540 - 1.0392
52 Week Range0.4700 - 2.5600
Volume124,797
Avg. Volume398,159
Market Cap8.86M
Beta (3Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-3.6330
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Trade prices are not sourced from all markets
  • Did You Manage To Avoid Ritter Pharmaceuticals's (NASDAQ:RTTR) Devastating 93% Share Price Drop?
    Simply Wall St.6 days ago

    Did You Manage To Avoid Ritter Pharmaceuticals's (NASDAQ:RTTR) Devastating 93% Share Price Drop?

    Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) shareholders should be happy to see the share price up 29% in the last...

  • GlobeNewswire7 days ago

    Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that it has received written notice from Nasdaq that the Company’s minimum bid price deficiency has been cured and that the Company is in compliance with all applicable listing standards. Accordingly, the scheduled hearing before the Hearings Panel to appeal the previous determination of non-compliance has been cancelled.

  • GlobeNewswire16 days ago

    Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the last patient has completed their final visit in the Company’s first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of lactose intolerance (LI), a study known as “Liberatus” (NCT03597516). The 557-subject clinical trial began enrollment in late June 2018 and completed on-time in just over a year.

  • GlobeNewswire28 days ago

    Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first Food and Drug Administration (FDA)-approved treatment for lactose intolerance (LI), today provided an update of its Phase 3 clinical trial and regulatory efforts.

  • GlobeNewswire2 months ago

    Ritter Pharmaceuticals Shares New Market Research Illuminating the Life Challenges of a Lactose Intolerance Sufferer

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today shared data from an independent research study conducted by JJN Consulting. The study included a survey of approximately 1,500 LI patients to gain deeper insights into their experiences and into the unmet needs apparent in LI today.

  • GlobeNewswire2 months ago

    Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019

    LOS ANGELES, May 14, 2019 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that.

  • GlobeNewswire2 months ago

    Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the final patient in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of Lactose intolerance (LI), a study known as the “Liberatus” study (NCT03597516), has completed the 30-day treatment dosing period. “We are excited to announce that the last of the 557 enrolled patients in our Liberatus trial has completed dosing and we remain on track for data readout in early Q4 2019,” said Andrew J. Ritter, CEO of Ritter Pharmaceuticals.

  • Will Ritter Pharmaceuticals, Inc.'s (NASDAQ:RTTR) Earnings Grow Over The Next Few Years?
    Simply Wall St.3 months ago

    Will Ritter Pharmaceuticals, Inc.'s (NASDAQ:RTTR) Earnings Grow Over The Next Few Years?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In December 2018, Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) released its latest earnings announcement, which signalled...

  • GlobeNewswire4 months ago

    Ritter Pharmaceuticals Reports Year End 2018 Financial Results and Provides Business Update

    LOS ANGELES, March 29, 2019 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the.

  • GlobeNewswire4 months ago

    Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), a condition afflicting more than 40 million people in the United States and millions more worldwide, today announced that it has completed, ahead of schedule, enrollment in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of LI, a study known as the “Liberatus” study (NCT03597516). “We are encouraged and pleased to have achieved this important milestone ahead of schedule.

  • GlobeNewswire5 months ago

    Dr. William Chey Highlights Unmet Medical Need of Lactose Intolerance and Potential for Phase 3 Drug Candidate RP-G28 in Expert Call Hosted by Ritter Pharmaceuticals

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today recaps remarks made by Dr. William Chey, Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan in an expert call hosted by the Company.

  • GlobeNewswire5 months ago

    Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that Dr. William Chey, Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan will be the subject of an expert call to be held on February 20, 2019 at 1:00 PM ET/10:00 AM PT.

  • What Type Of Shareholder Owns Ritter Pharmaceuticals, Inc.’s (NASDAQ:RTTR)?
    Simply Wall St.5 months ago

    What Type Of Shareholder Owns Ritter Pharmaceuticals, Inc.’s (NASDAQ:RTTR)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Read More...

  • GlobeNewswire6 months ago

    Ritter Pharmaceuticals To Present at Noble Capital Markets’ Fifteenth Annual Investor/Equity Conference on January 28, 2019

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that Andrew Ritter, CEO, will be a featured presenter at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference on January 28th at the W Hotel, Fort Lauderdale, Florida. Mr. Ritter will provide an overview of the company's Phase 3 program in lactose intolerance, including its pivotal Phase 3 trial, “Liberatus” which is currently underway, and other important business highlights.

  • GlobeNewswire7 months ago

    Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that it has passed the 50 percent enrollment point in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of LI, a study known as the “Liberatus” study. “We are pleased to have achieved this important milestone in study enrollment and we remain on track with our projected timeline for the completion of the Liberatus study in the second half of 2019,” said Andrew J. Ritter, CEO of Ritter Pharmaceuticals.

  • GlobeNewswire8 months ago

    Consolidated Research: 2018 Summary Expectations for E*TRADE Financial, Ballantyne Strong, Lincoln Educational Services, Electro-Sensors, Capital Southwest, and Ritter Pharmaceuticals — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire8 months ago

    Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Progress

    LOS ANGELES, Nov. 09, 2018 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate.

  • GlobeNewswire8 months ago

    Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced the closing on November 5, 2018 of its previously announced private placement of Series B convertible preferred stock and warrants to certain accredited investors, including two current institutional holders of our Series A convertible preferred stock, a key vendor and a member of the Company’s board of directors. The Company received gross proceeds of approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.

  • GlobeNewswire9 months ago

    Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that it has entered into a definitive agreement with certain accredited investors, including two current institutional holders of our Series A convertible preferred stock, a key vendor and a member of the Company’s board of directors, for a private placement of newly designated Series B convertible preferred stock and warrants.